Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Acutely Decompensated Heart Failure with Diuretic Resistance and CKD
NCT05305495Phase 4Completed
- Sponsor
- McGill University Health Centre
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in Acute Heart Failure (AHF), sponsored by McGill University Health Centre. Primary endpoint: Diuretic effect of empagliflozin in association with furosemide at Day 1. Started Dec 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT05305495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305495.